Janakiraman Subramanian, MD, MPH

Financial relationships

  • Attribution:
    Self
    Type of financial relationship:
    Professional Services
    Ineligible company:
    Astra Zeneca
    Topic:
    Speaker/Advisor
    Date added:
    11/01/2023
    Date updated:
    10/09/2025
  • Attribution:
    Self
    Type of financial relationship:
    Professional Services
    Ineligible company:
    Daiichi
    Topic:
    Advisor
    Date added:
    11/01/2023
    Date updated:
    10/09/2025
  • Attribution:
    Self
    Type of financial relationship:
    Professional Services
    Ineligible company:
    Jazz Pharma
    Topic:
    Speaker
    Date added:
    11/01/2023
    Date updated:
    10/09/2025
  • Attribution:
    Self
    Type of financial relationship:
    Professional Services
    Ineligible company:
    Janssen
    Topic:
    Speaker
    Date added:
    11/01/2023
    Date updated:
    10/09/2025
  • Attribution:
    Self
    Type of financial relationship:
    Professional Services
    Ineligible company:
    Oncohost
    Topic:
    speaker
    Date added:
    11/01/2023
    Date updated:
    10/09/2025
  • Attribution:
    Self
    Type of financial relationship:
    Professional Services
    Ineligible company:
    Pfizer
    Topic:
    advisor
    Date added:
    11/01/2023
    Date updated:
    10/09/2025
  • Attribution:
    Self
    Type of financial relationship:
    Professional Services
    Ineligible company:
    GLG
    Topic:
    advisor
    Date added:
    11/01/2023
    Date updated:
    10/09/2025
  • Attribution:
    Self
    Type of financial relationship:
    Professional Services
    Ineligible company:
    Guidepoint
    Topic:
    advisor
    Date added:
    11/01/2023
    Date updated:
    10/09/2025
  • Attribution:
    Self
    Type of financial relationship:
    Professional Services
    Ineligible company:
    Cancer Expert Now
    Topic:
    advisor
    Date added:
    11/01/2023
    Date updated:
    10/09/2025
  • Attribution:
    Self
    Type of financial relationship:
    Professional Services
    Ineligible company:
    Regeneron/Sanofi
    Topic:
    advisor
    Date added:
    11/01/2023
    Date updated:
    10/09/2025

Pages

Return to 2025 Inova Schar Cancer Institute Grand Rounds: Chasing Solutions to Challenges with Immunotherapy